Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to test the safety of a combination of the study drug called WST11 and PDT. Photodynamic therapy (PDT) is a type of ablation therapy (treatment which destroys tumor cells) which has been previously approved for the treatment of patients with other cancers. It works by using a drug that is given through the vein and then is activated in the tumor by light administered during endoscopy, which results in destruction of the cancer cells.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03617003
Study type Interventional
Source Memorial Sloan Kettering Cancer Center
Contact
Status Active, not recruiting
Phase Phase 1
Start date August 1, 2018
Completion date December 2, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT02547350 - Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors After Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas Phase 2
Recruiting NCT04948528 - Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for Upper Tract Urothelial Carcinoma Detection
Recruiting NCT05917158 - A Study of RC48-ADC Combined With JS001 For Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma Phase 2
Recruiting NCT02923557 - Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma Patients Phase 2
Recruiting NCT02969083 - Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma Phase 2
Recruiting NCT03544437 - Feasibility and Safety of Extraperitoneal Laparoscopic Extended Retroperitoneal Lymph Node Dissection at Time of Nephroureterectomy for Upper Tract Urothelial Carcinoma
Recruiting NCT03230201 - Lymph Node Dissection in High-risk UTUC(Upper Tract Urothelial Carcinoma) N/A
Recruiting NCT02740426 - Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Diagnostic Ureteroscopy for Primary Upper Tract Urothelial Carcinoma Patients Phase 2